Recombinant DNA Advisory Committee - 06/1-2/92 
I. CALL TO ORDER 
Dr. Murray (Chair) called the meeting to order at 9:00 a.m., on June 1, 1992. She 
welcomed and introduced the new RAC members, Drs. Secundy, Zallen, Dronamraju, 
DeLeon, and D. Miller. Dr. Murray noted that the RAC serves as advisor to the 
Director of the National Institutes of Health (NIH). The Director may accept, reject, or 
send the RAC's recommendations back to the committee for further deliberation. 
Dr. Murray stated that a quorum was present and outlined the order in which speakers 
would be recognized. The primary and secondary reviewers will present their overviews 
of the protocol, followed by responses from the principal investigators of the protocols. 
The Chair will then recognize other RAC members, ad hoc consultants, other NIH and 
Federal employees, the public who has submitted written documentation, followed by the 
public at large. 
II. MINUTES OF THE FEBRUARY 10-11, 1992, MEETING 
Dr. Murray called on Dr. Brinckerhoff to comment on the minutes of the February 10- 
11, 1992, meeting of the RAC. Dr. Brinckerhoff stated that the minutes were an 
accurate reflection of the committee's deliberations. Dr. Carmen concurred. 
The RAC unanimously approved a motion made by Dr. Carmen and seconded by Dr. 
Brinckerhoff to approve the minutes. 
III. REPORT ON HUMAN GENE TRANSFER PROTOCOLS ENTITLED: 
(1) AUTOLOGOUS BONE MARROW TRANSPLANT FOR CHILDREN WITH ACUTE 
MYELOGENOUS LEUKEMIA (AML) IN FIRST COMPLETE REMISSION: USE OF 
MARKER GENES TO INVESTIGATE THE BIOLOGY OF MARROW 
RECONSTITUTION AND THE MECHANISM OF RELAPSE , , (2) A PHASE I /II TRIAL 
OF HIGH DOSE CARBOPLATIN AND ETOPOSIDE WITH AUTOLOGOUS MARROW 
SUPPORT FOR TREATMENT OF STAGE D NEUROBLASTOMA IN FIRST 
REMISSION: USE OF MARKER GENES TO INVESTIGATE THE BIOLOGY OF 
MARROW RECONSTITUTION AND THE MECHANISM OF RELAPSE, AND (3) A 
PHASE II TRIAL OF HIGH-DOSE CARBOPLATIN AND ETOPOSIDE WITH 
AUTOLOGOUS MARROW SUPPORT FOR TREATMENT OF 
RELAPSE/REFRACTORY NEUROBLASTOMA WITHOUT APPARENT BONE 
MARROW INVOLVEMENT /DR. BRENNER: 
Status Report-Dr. Brenner 
Dr. Murray called on Dr. Malcolm Brenner of St. Jude Children's Research Hospital, 
Memphis, Tennessee, to present an update of his previously approved protocols. Dr. 
[672] 
Recombinant DNA Research, Volume 15 
